Onychomycosis treated with a dilute povidone-iodine/dimethyl sulfoxide preparation
Kara Capriotti1, Joseph A Capriotti2
1ALC Therapeutics, LLC, Springhouse, PA, USA ; Bryn Mawr Skin and Cancer Institute, Rosemont, PA, USA.
Background:
Povidone-iodine (PVP-I) 10% aqueous solution is a well-known, nontoxic, commonly used topical antiseptic with no reported incidence of fungal resistance. We have been using a low-dose formulation of 1% PVP-I (w/w) in a solution containing dimethyl sulfoxide (DMSO) in our clinical practice for a variety of indications. Presented here is our clinical experience with this novel formulation in a severe case of onychomycosis that was resistant to any other treatment.
Findings:
A 49-year-old woman who had been suffering from severe onychomycosis for years presented after failing to find any remedy including over the counter (OTC), topical, and systemic oral prescribed therapies.
Conclusion:
The topical povidone-iodine/DMSO system was very effective in this case at alleviating the signs and symptoms of onychomycosis. This novel combination warrants further investigation in randomized, controlled trials to further elucidate its clinical utility.
Insights
A novel topical povidone-iodine/dimethyl sulfoxide formulation effectively treated severe, treatment-resistant onychomycosis. This combination therapy shows promise for fungal nail infections.
Area of Science:
- Dermatology
- Mycology
- Pharmaceutical Science
Background:
- Povidone-iodine (PVP-I) 10% is a safe topical antiseptic with no known fungal resistance.
- A low-dose 1% PVP-I in dimethyl sulfoxide (DMSO) formulation is used clinically.
- This case report details its use in a severe, refractory onychomycosis case.
Observation:
- A 49-year-old female patient presented with severe onychomycosis.
- Previous treatments including OTC, topical, and oral therapies were ineffective.
Findings:
- The topical povidone-iodine/DMSO combination demonstrated high efficacy.
- Significant alleviation of onychomycosis signs and symptoms was observed.
Implications:
- This novel PVP-I/DMSO combination warrants further investigation.
- Randomized controlled trials are needed to confirm clinical utility for onychomycosis treatment.
More Related Videos
Related Concept Videos
Hand hygiene
Hand washing...
Antifungal Agents


